Who are Low Dose PF-07328948's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, BNT162b2 BA.4/5 bivalent, Combination (Bivalent) BNT162b2 and BNT162b2 OMI, Raxtozinameran 6 months to 4 years of age, BNT162b2, bivalent BNT162b2 (original/Omi BA.4/BA.5).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-pf-07328948.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Low Dose PF-07328948 — Competitive Intelligence Brief

Low Dose PF-07328948 (low-dose-pf-07328948) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: small molecule. Area: Infectious Disease.

marketed small molecule SARS-CoV-2 virus Infectious Disease Live · refreshed every 30 min

Target snapshot

Low Dose PF-07328948 (low-dose-pf-07328948) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low Dose PF-07328948 TARGET	low-dose-pf-07328948	Pfizer	marketed	small molecule	SARS-CoV-2 virus
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
BNT162b2 BA.4/5 bivalent	bnt162b2-ba-4-5-bivalent	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus
Combination (Bivalent) BNT162b2 and BNT162b2 OMI	combination-bivalent-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	vaccine	SARS-CoV-2 virus
Raxtozinameran 6 months to 4 years of age	raxtozinameran-6-months-to-4-years-of-age	Pfizer	marketed	viral entry inhibitor	SARS-CoV-2 virus
BNT162b2	bnt162b2	Pfizer	marketed	vaccine	SARS-CoV-2 virus
bivalent BNT162b2 (original/Omi BA.4/BA.5)	bivalent-bnt162b2-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (small molecule class)

Pfizer · 5 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 4 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Cipla BioTec Pvt. Ltd. · 1 drug in this class
ChemRar Research and Development Institute, LLC · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Dilafor AB · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low Dose PF-07328948 — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-pf-07328948. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab